Summary Although breast cancer is perceived to be relatively chemosensitive, cytotoxic drug therapy only leads to cure in the adjuvant setting. In advanced disease, primary resistance and inadequate cell kill may be important in determining the lack of a durable response to cytotoxics, but for an individual patient's tumour there is no consistent way of determining the importance of these two factors. An adaptation of Skipper's log cell kill model of tumour response to chemotherapy was applied to serial tumour measurements of 46 locally advanced primary breast carcinomas undergoing neoadjuvant chemotherapy. Assuming a log-normal distribution of errors in the clinically measured volumes, the model produced, for each tumour separately, in vivo estimates of proportional cell kill, initial resistance and tumour doubling times during therapy. After 4 weeks' treatment, these data could then be used to predict subsequent tumour volumes with good accuracy. In addition, for the 13 tumours that became operable after the neoadjuvant chemotherapy, there was a significant association between the final volume as predicted by the model and the final pathological volume (P<0.05). This approach could be usefully employed to determine those tumours that are primarily resistant to the treatment regimen, permitting changes of therapy to more effective drugs at a time when the tumour is clinically responding but destined to progress.
It is well recognised, from both clinical and laboratory work, that most cancers exhibit primary or acquired resistance to many cytotoxic drugs, and that overgrowth of these resistant cells leads to ultimate treatment failure (Skipper, 1978) . This is one of the main reasons for the failure to cure many malignancies (Harris, 1985) . In trying to assess clinically the tumour response to treatment, one has to rely on measurements that are often rather crude. For example, clinical or radiological measurements are only possible if there are at least 108 cells present, and even using the most sensitive tumour markers a total tumour burden of below 10' is usually undetectable. Following chemotherapy, malignancies can be rendered undetectable as defined by clinical or radiological tests -the so-called complete response or CR. But only prolonged follow-up tells if a cure has been achieved.
In the laboratory, one can identify cell lines that respond to treatment and those that do not. However, testing for chemosensitivity of patients' individual tumours in a manner analagous to anti-microbial sensitivity assays is not generally practicable; indeed in a recent study with single-agent 5-fluorouracil an in vitro sensitivity assay was only possible in 69% of assessable patients (Elledge et al., 1995) .
A model of tumour response to therapy, individualised for each tumour, has previously been described for breast cancer (Priore, 1966) , but using an S-shaped cumulative doseresponse curve, rather than the more generally accepted logkill response. In this earlier model, the intention was to improve on simple clinical measurements of metastases to permit better assessment of the efficacy of cytotoxic agents. No attempt was made to predict subsequent tumour behaviour or pathological volumes. We hypothesised that incorporating primary resistance as well as cell kill in a model might assist the assessment of the efficacy of the cytotoxics and, furthermore, enhance the prediction of subsequent failure, permitting earlier changes in therapy.
The model
The model assumes exponential cell growth, and derives estimates of the actual proportions of sensitive and resistant cells as a consequence of the change in tumour volume with each treatment cycle. The tumour doubling time d is assumed to be a constant throughout the time of treatment. The theory of the model has been described previously (Birkhead and Gregory, 1984) , and validated using small-cell lung cancer monitored with serial computerised tomography (CT) scans (Gregory et al., 1990) . It is represented diagrammatically in Figure 1 ; it assumes that all cells killed by one cycle of therapy can no longer grow and furthermore, that they make no contribution to the tumour volume recorded just before the subsequent cycle.
Skipper et al. (1964) found that in the mouse model of leukaemia a given dose of chemotherapy killed a constant proportion of the cells present, and described this as the logkill model. We have used this concept to describe the cell kill in our model, representing by k the proportion of the tumour (Gregory et al., 1990) , assumed a log-normal distribution of errors, i.e. that the error increases with increasing tumour size. The second version assumed that there was a normal distribution of errors, i.e. that the error distribution is independent of the volume, but we were unable to fit the model to our data using this assumption. All data presented have therefore been generated by the model assuming a log-normal error distribution.
The clinical tumour measurements were performed using calipers to provide data for assessment using UICC criteria of response, and are therefore two orthogonal diameters a and b. In order to calculate tumour volumes from them, we have had to approximate to the third dimension as the average of the other two diameters and have assumed the tumour volume to be an ellipsoid:
The volume of the tumours that were surgically excised after the 12 weeks chemotherapy was estimated using the same formula, unless only one maximum dimension a was reported, in which case the formula used was:
All patients were subjected to a pretreatment biopsy, both for histological proof of breast cancer and to estimate the oestrogen receptor concentration. In many cases this was performed by removing a palpably malignant ipsilateral axillary node. When this was not possible, a wedge biopsy of the primary was performed. We have assumed that it is impossible to determine how this surgical trauma affected the measured volumes; therefore to minimise this potential source of error, all biopsied lesions were analysed only from the start of the fifth week of treatment, thus allowing at least 29 days to elapse from the time of surgery before the tumour measurements were used. Since the model assumes no significant acquisition of resistance during therapy, the parameters can be derived from a minimum of four sequential measurements at any point during early therapy. 
Statistical methods

Results
In 16 patients there were 22 tumours that had not been biopsied, and the model was applied to the first four tumour measurements. The cell kinetic parameters are shown in Table I . Only six tumours are estimated to have primary resistant cells, with the highest value being 39%. In 9/22 tumours, the model estimated the tumour doubling time on therapy to be between 6 and 57 days. However, in the remaining 13 tumours the model fitted best if there was no apparent growth during treatment, and the doubling time is given as oo in Table I -for these tumours the model assumes an artificially imposed maximum doubling time of 10 000 days.
In 30 patients there were 30 tumours that had been biopsied before treatment, and these were modelled using volumes from day 29 onwards. Seven Figure 2 . It can be seen that most of the response in these four tumours had occurred by day 29, and that the model was therefore attempting to derive the parameters from a plateau in the response curve. There was no other obvious characteristic in these patients, except that all but one had been treated on the second (AcF) regimen. Although the model could be successfully applied in two of these four tumours (data not shown) using tumour volumes from day 1, this was not possible for all 30 tumours that had been biopsied.
The values for cell kill and resistance for the remaining 16 biopsied tumours (derived from the tumour measurements in the fifth cycle onwards) to which the model was successfully applied, are also seen in Table I and are similar to the unbiopsied lesions with a mean cell kill of 34% and mean resistance of 9%. Again it can be seen that in the majority (10/16) the model estimates that there was no regrowth during the therapy, and the doubling time has been given as 00.
The model parameters were then used to predict all the tumour measurements recorded, both those used to derive the parameters and those for the subsequent courses. Table II shows the percentage variability between the clinical volumes and those predicted by the model, and this is depicted graphically in Figure 3 . The x-axis corresponds to the variability between the four actual volumes to which the model was applied, and the 'best fit' volumes predicted by the model. On the y-axis are the variabilities between the actual and model predicted volumes beyond those first four volumes. There is a good correlation between these two figures, which is statistically significant, suggesting that where there is a good fit over the first four volumes the model will predict the subsequent volumes more accurately.
The final volumes for the 13 patients who had surgery at the end of the 12 weeks' chemotherapy are set out in Table  III , and there is a good correlation between the final volume predicted by the model and both the final measured volume and the pathological volume (Figure 4 ). In three patients there was a complete pathological response, and for these three patients the model estimated zero primary resistance. However, when all 13 patients are assessed this result is not significant at the 5% level, possibly because of the small numbers.
A clear correlation was found between all the actual tumour volumes and those predicted by the model (Figures  5a and b) . This was the case both for the tumours that had not been biopsied (Figure 5a , r2=0.893, P<0.00001), and those that had been subjected to a biopsy (Figure 5b There is little doubt that changes in cell proliferation, and in the expression of c-erbB-2 and p53 (Gardin et al., 1994) , can occur as a consequence of neoadjuvant chemotherapy, but there are no firm data on how these changes could be The patients were all treated with one of two different regimens. Those given CAF had all the cytotoxics administered in the first 3 days of each week, whereas in AcF, weekly doxorubicin is combined with continuous 5-fluorouracil. The current model does not assume such continuous exposure to a cytotoxic. However, there was no significant difference between the two treatments in terms of cell-kinetic parameters, or in the accuracy of the model-predicted volumes. It should also be noted that there was no significant difference in the proportion of tumours with no apparent growth on therapy between the two treatment arms -so it cannot be seen as an effect of the continuous 5-FU in the group of patients treated with AcF.
We have shown here that a relatively simple mathematical model can be applied to a set of clinically derived measurements and in many cases apparently reasonable cell cycle parameters can be deduced. It would be particularly interesting to compare these figures with data derived from in vitro studies on cells from these tumours, but currently that is not possible. However, if the parameters are at all realistic, then they should produce predictions for subsequent tumour volumes that are close to those actually recorded. Formal statistical inferences are difficult, but Figure 3 shows that where the model fits tightly over the first four volumes it more accurately predicts the subsequent volumes. This may be because the measurements are intrinsically more accurate in some tumours; or perhaps more likely that there are some tumours for whom this model provides a better description of the underlying kinetics. However, in many cases where the subsequent predictions are less accurate, the actual clinical volumes are very small (usually less than 1 cm3).
In addition we found a correlation between the modelpredicted final volume and the pathological volume in the 13 patients who had surgery at the end of their treatment, with the three patients in pathological CR having no resistant cells according to the model. As can be seen from Figure 4 , this correlation is not good enough to accurately predict the pathological volume, but the model is at least as accurate as clinical measurement just before surgery.
Given the potential for errors in the clinical measurements, the above results are impressive and demonstrate the validity of applying this type of model, even with the assumptions that have had to be made. It is not clear, therefore, whether the differences between model and measured volumes represent errors in the clinical estimation of the tumour size or inaccuracies inherent in the model or its parameters being imprecise. Pain et al. (1992) suggest that clinical measurements overestimate the size of small breast tumours and underestimate large ones, although they concluded overall that ultrasound was no better, tending to underestimate tumour size. Forouhi et al. (1994) , on the other hand found a much better correlation between pathological size and that measured by ultrasound, although there was also a significant correlation between pathological and clinically measured tumours. Warr et al. (1984) found that clinical measurement of lesions below 2.6 cm had a much higher percentage of false-positive partial responses, although they were not able to compare the actual measurements with a 'gold standard' pathological size, as in the above two studies. As the tumours in our study all regressed on chemotherapy, these studies all suggest that there are likely to be significant errors in the clinical measurements that will not lessen as the tumours shrink. Indeed, Figures 5a and b, together with Table II, suggests that the error in the clinical volume may be larger for smaller tumours. It is unclear how this could be best accommodated mathematically, as such smaller volumes only appear during subsequent treatment cycles. However, it does not pose a significant problem for the model derivation of the cell-kinetic parameters as, with the exceptions of the nodes measured in patients 4 and 8, all other volumes used to derive the parameters were based on tumour dimensions of greater than 1.5 cm.
There were a small number of tumours to which the model could not be applied. In most cases this was because of unreliable or inadequate clinical volume measurements, but in four cases that had all been biopsied it transpired that the model was applied to a plateau of tumour response (see Figure 2 ). Earlier application of the model in two of these four cases was successful, but as it was only with the knowledge of the subsequent volumes that the presence of a response plateau was apparent, such an approach could not be entertained when using this model to prospectively predict tumour behaviour. Indeed, if the model was applied from the first treatment cycle for all tumours, thus ignoring the impact of surgical trauma on tumour measurements, it does not provide overall as close a fit to the measured volumes. Clearly it would be helpful to either avoid biopsy of the tumour to be measured, or to have a method of differentiating the tumour from any haematoma. Figure 6 shows that there is a trend for the tumour doubling time to rise with initial tumour volume, which is in keeping with a different model of tumour growth, such as Gompertzian (Gompertz, 1825; Laird, 1964) . It would be interesting to apply such a model to these data, but it would require estimation of one additional parameter, ,B (which represents the rate at which the growth falls away from exponential). Given the potential for errors in the measurements as discussed above, it might be better to get more accurate volume measurements first, for example using ultrasound. In contrast however, Brown et al. (1984) showed that in a large series of primary breast cancers there was no 
